Daniel Storey
YOU?
Author Swipe
View article: Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screening
Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screening Open
Background: Disease modeling is vital for our understanding of disease mechanisms and for developing new therapeutic strategies. Accurately modeling the intact tumor microenvironment (TME) is increasingly recognized as essential for gainin…
View article: Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study
Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study Open
Background Intravenous [IV] infliximab is a well-established therapy for inflammatory bowel diseases [IBD] patients. A subcutaneous [SC] formulation of infliximab [CT-P13] has recently been shown to be as effective as IV infliximab after t…
View article: A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II
A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II Open
Summary Background The optimal choice of biological agents after failure of anti‐tumour‐necrosis‐factor‐(TNF)α agent in Crohn’s disease (CD) is yet to be defined. Aims To assess the effectiveness and safety of ustekinumab compared to vedol…
View article: PMO-28 Efficacy of subcutaneous infliximab in perianal crohn’s disease
PMO-28 Efficacy of subcutaneous infliximab in perianal crohn’s disease Open
Background A new subcutaneous (SC) formulation of infliximab has recently been approved for the management of inflammatory bowel diseases (IBD). In the registration clinical trial, the efficacy of SC IFX was comparable to intravenous (IV) …
View article: PMO-16 Efficacy and safety of elective switching from intravenous to subcutaneous infliximab: A multi-centre cohort study
PMO-16 Efficacy and safety of elective switching from intravenous to subcutaneous infliximab: A multi-centre cohort study Open
Introduction Intravenous (IV) infliximab is a well-established therapy for inflammatory bowel diseases (IBD) patients. A subcutaneous (SC) formulation of infliximab has recently been shown to be as effective as IV infliximab in a randomise…
View article: P496 Efficacy and safety of elective switching of inflammatory bowel disease patients from intravenous to subcutaneous infliximab (IFX): a multi-centre cohort study
P496 Efficacy and safety of elective switching of inflammatory bowel disease patients from intravenous to subcutaneous infliximab (IFX): a multi-centre cohort study Open
Background A subcutaneous (SC) formulation of IFX has recently been shown to be as effective as intravenous (IV) IFX in a randomised trial but there are no real world data to support elective switching. We aimed to assess the effectiveness…
View article: P352 A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn’s disease. The Cross Pennine study II
P352 A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn’s disease. The Cross Pennine study II Open
Background The best choice of biological agents after failure to an anti-tumour necrosis factor (TNF)α agent in patients with Crohn’s disease (CD) is yet to be defined. Real-world data dealing with this issue are still emerging. Methods Th…
View article: P162 Comparative effectiveness of vedolizumab and ustekinumab in anti-TNF refractory Crohn’s disease: Multi-centre retrospective cohort study
P162 Comparative effectiveness of vedolizumab and ustekinumab in anti-TNF refractory Crohn’s disease: Multi-centre retrospective cohort study Open
Introduction Anti-tumour necrosis factor (TNF) agents are effective in Crohn's disease (CD), but up to 30% of patients fail to respond or develop intolerance and require alternative biological therapy. Both vedolizumab and ustekinumab are …
View article: PWE-061 Predictors of remission to vedolizumab therapy in a combined inflammatory bowel diseases cohort
PWE-061 Predictors of remission to vedolizumab therapy in a combined inflammatory bowel diseases cohort Open
Introduction The response to the anti-integrin-α4β7 antibody, vedolizumab, is variable in both Crohn's disease and ulcerative colitis. Apart from prior exposure to anti-TNF agents, there are very few clinical predictors of response to vedo…
View article: PWE-060 Baseline calprotectin predicts steroid free remission with biological therapy in ulcerative colitis at 1 year
PWE-060 Baseline calprotectin predicts steroid free remission with biological therapy in ulcerative colitis at 1 year Open
Background Response to the anti-tumour necrosis factor (TNF) agents and the anti-integrin-α4β7 antibody, vedolizumab, in ulcerative colitis (UC) is variable. There are few clinical predictors of long term efficacy to biological therapy apa…
View article: P795 A specialised inflammatory bowel disease service provides equality of access to healthcare, irrespective of deprivation indices
P795 A specialised inflammatory bowel disease service provides equality of access to healthcare, irrespective of deprivation indices Open
There is a strong association between deprivation and poor healthcare outcomes. Several factors combine to influence this outcome, including having poorer access to healthcare. The Merseyside region is amongst the most deprived areas in th…
View article: PTH-074 Baseline calprotectin does not predict response to biological therapy in ulcerative colitis
PTH-074 Baseline calprotectin does not predict response to biological therapy in ulcerative colitis Open
Introduction Response to biological drugs in ulcerative colitis (UC) is variable with induction response rates of 64.5% (vs 29.3% for placebo), 50.4% (vs 34.6% for placebo), 51.0% (vs 30.3% for placebo), 47.1% (vs 25.5% for placebo) for in…